Pablo Cagnoni has joined cell therapy developer Rubius Therapeutics as CEO. Cagnoni’s career includes work as both an oncologist and a pharmaceutical executive. He was most recently president and CEO of South San Francisco, CA, cancer drug developer Tizona Therapeutics. Rubius, based in Cambridge, MA, is engineering red blood cells with therapeutic properties. The company raised $100 million in March as it prepares to bring its first red blood cell therapy—for a yet-to-be-disclosed indication—into clinical testing.
